RecruitingPHASE1, PHASE2NCT05839275

The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fudan University
Principal Investigator
Zhen Zhang, M.D, PH.D
Fudan University
Intervention
Surufatinib(drug)
Enrollment
52 target
Eligibility
18-70 years · All sexes
Timeline
2022 – 2029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05839275 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma →

← Back to all trials